Acorda Therapeutics hopes its products really get on your nerves. The company is developing prescription drugs that aim to restore neurological function for patients with spinal cord injury and other central nervous system disorders. The company's marketed drugs include muscle spasm controller Zanaflex along with Ampyra, which enhances conduction in nerves damaged by blunt trauma or from multiple sclerosis (MS). It purchased the US rights to Zanaflex from Elan Corporation but developed Amprya itself. Acorda is working with Biogen Idec to market Ampyra outside the US. Acorda's other drug candidates include potential therapies for MS and central nervous system, cardiac, and spinal cord injuries.